Hepatocellular carcinoma risk-stratification based on ASGR1 in circulating epithelial cells for cancer interception
Metadatos
Mostrar el registro completo del ítemAutor
Roa Colomo, Amparo; López Garrido, María Ángeles; Molina Vallejo, María Pilar; González Sánchez, Mercedes; Aranda García, Violeta; Salmerón Escobar, Francisco Javier; Lorente Acosta, José Antonio; Serrano Fernández, María José; Garrido Navas, María del CarmenEditorial
Frontiers
Materia
Hepatocellular carcinoma Liver cirrhosis Circulating tumor cells Precision medicine Cancer interception
Fecha
2022-11-28Referencia bibliográfica
Roa-Colomo A... [et al.] (2022), Hepatocellular carcinoma riskstratification based on ASGR1 in circulating epithelial cells for cancer interception. Front. Mol. Biosci. 9:1074277. doi: [10.3389/fmolb.2022.1074277]
Patrocinador
Regional Ministry of Health of Andalusia; Ministry of Economy, Competitiveness, Enterprises and Universities PC-0522-2016 PC-0267-2017 PC-0033-2017; Health Institute Carlos III (ISCIII) DOC_01682 CD18/00126Resumen
Purpose: Lack of diagnostic and prognostic biomarkers in hepatocellular
carcinoma impedes stratifying patients based on their risk of developing
cancer. The aim of this study was to evaluate phenotypic and genetic
heterogeneity of circulating epithelial cells (CECs) based on
asialoglycoprotein receptor 1 (ASGR1) and miR-122-5p expression as
potential diagnostic and prognostic tools in patients with hepatocellular
carcinoma (HCC) and liver cirrhosis (LC).
Methods: Peripheral blood samples were extracted from LC and HCC patients
at different disease stages. CECs were isolated using positive immunomagnetic
selection. Genetic and phenotypic characterization was validated by double
immunocytochemistry for cytokeratin (CK) and ASGR1 or by in situ hybridization
with miR-122-5p and CECs were visualized by confocal microscopy.
Results: The presence of CECs increased HCC risk by 2.58-fold, however, this
was only significant for patients with previous LC (p = 0.028) and not for those
without prior LC (p = 0.23). Furthermore, the number of CECs lacking
ASGR1 expression correlated significantly with HCC incidence and absence
of miR-122-5p expression (p = 0.014; r = 0.23). Finally, overall survival was
significantly greater for patients at earlier cancer stages (p = 0.018), but this difference was only maintained in the group with the presence of CECs (p =
0.021) whereas progression-free survival was influenced by the absence of
ASGR1 expression.
Conclusion: Identification and characterization of CECs by ASGR1 and/or miR-
122-5p expression may be used as a risk-stratification tool in LC patients, as it
was shown to be an independent prognostic and risk-stratification marker in LC
and early disease stage HCC patients.